JointHealth™ express   December 16, 2010

Updated and newly designed report card

Arthritis Consumer Experts is pleased to announce the updated and newly designed Report Card on provincial formulary reimbursement listings for biologic response modifiers.

The report card now ranks each province according to whether it lists nine biologic response modifiers for four of the most common types of inflammatory arthritis: rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. This change reflects the inclusion of certolizumab pegol (Cimzia®) and golimumab (Simponi®) on some formularies, as well as the recent recommendation by the Common Drug Review that tocilizumab (Actemra®) be covered by provincial drug plans.

The report card continues to provide the latest listing criteria for this important group of arthritis medications on all the provincial formularies in Canada.

Arthritis Consumer Experts' report card is a valuable information tool for researchers, physicians, government, and people with arthritis – and it is simple to use.

Please click here to view the updated report card. Arthritis Consumer Experts welcomes any feedback you may have: